Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apcmin/+ mouse

Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor Inhibition

(2009) N. A. Dallas et al.   CANCER RESEARCH

Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma

(2009) C. Desbois-Mouthon et al.   CLINICAL CANCER RESEARCH

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

(2009) J. Zha et al.   MOLECULAR CANCER THERAPEUTICS

Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor

(2009) C. P. Carden et al.   MOLECULAR CANCER THERAPEUTICS

Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis

(2009) S. Kaulfuss et al.   MOLECULAR CANCER THERAPEUTICS

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

(2008) E. Buck et al.   CANCER RESEARCH

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 Inhibitors

(2008) F. Huang et al.   CANCER RESEARCH

The Type 1 Insulin-Like Growth Factor Receptor Pathway

(2008) M. M. Chitnis et al.   CLINICAL CANCER RESEARCH

Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

(2008) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL ONCOLOGY

HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924

(2008) P. Haluska et al.   MOLECULAR CANCER THERAPEUTICS

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE